BioStock Investor Meeting March 2022 | AlzeCure
AlzeCure’s CEO Martin Jönsson presents the company at BioStock Investor Meeting in March 2022.
0:00 Welcome
0:16 Agenda
0:34 What is AlzeCure Pharma?
1:41 Business model
1:57 Pipeline of small-molecule programs
2:44 Alzheimer’s disease
3:09 Increasing patient population
3:22 Progressive and lethal disorder
4:12 Market potential
4:31 Two Alzheimer’s platforms
5:15 Alztatin- what happens in the brain during Alzheimer’s?
6:16 Film about Alztatin
7:33 Alzheimer’s disease modifier
8:06 Alztatin vs antibodies
9:12 NeuroRestore
10:25 Chronic pain – second focus area
10:56 Two platforms in chronic pain
11:44 ACD440 – novel TRPV1 antagonist
12:20 Neuropathic pain market
12:46 Milestones and activities 2022
13:32 Why invest in AlzeCure?
14:12 Rights issue
14:44 Q&A
Also watch CEO interview about the AlzeCure’s development and the rights issue | 2022: https://youtu.be/SNpRLiEsSyQ
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: https://www.linkedin.com/company/biostock
Facebook: https://www.facebook.com/biostock.se
Twitter: https://twitter.com/BioStock_SWE
#biostock #lifescience #Alzecure
About BioStock
BioStock is Scandinavia’s leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office is found at Medicon Village in Lund, one of Sweden’s foremost innovation clusters for life science companies, while our second editorial office is located in central Stockholm with proximity to both life science companies and financial players. We have TV studios on both sites.
